TSR 042

Drug Profile

TSR 042

Alternative Names: TSR-042

Latest Information Update: 05 May 2017

Price : $50

At a glance

  • Originator AnaptysBio
  • Developer TESARO
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Solid tumours

Most Recent Events

  • 27 Apr 2017 Phase-III clinical trials in Solid tumours (Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 27 Apr 2017 TESARO announces intention to submit BLA to USFDA
  • 27 Apr 2017 TESARO plans to initiate label expansion trials in multiple Cancers (Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top